Summary of Altimmune's Conference Call Company Overview - **Company**: Altimmune - **Key Executives Present**: Jerry Durso (CEO), Christophe Arbet-Engels (CMO), Greg Weaver (CFO) [1][2] Industry and Product Focus - **Industry**: Biotech, specifically focusing on liver diseases such as Metabolic Associated Steatotic Hepatitis (MASH), Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD) - **Key Product**: Pemvidutide, a dual-action drug targeting glucagon and GLP-1 receptors [4][12] Key Highlights and Core Points Clinical Progress - **MASH Trials**: Significant progress in the Phase 2 MASH trial with 24-week and 48-week data showing potential for pemvidutide as a differentiated product in the MASH space [4][5] - **AUD Trials**: Enrollment ahead of schedule with top-line data expected in Q3 2026 [8] - **ALD Trials**: Enrollment expected to complete this year with two main readouts at 24 weeks and 48 weeks [43] Financial Position - **Balance Sheet**: Focus on strengthening the balance sheet through a combination of debt and equity, with discussions ongoing with strategic partners [6] - **Capital Allocation**: Emphasis on ensuring sufficient capital for the Phase 3 trial initiation [6] Differentiation of Pemvidutide - **Mechanism of Action**: Unique one-to-one ratio of glucagon and GLP-1, showing strong effects on fibrosis and MASH resolution [12] - **Tolerability**: Lower discontinuation rates compared to competitors, with a focus on preserving lean mass during weight loss [12][13] - **Data Insights**: Positive 48-week data indicating a clear dose response and strong anti-fibrotic effects [19] Phase 3 Trial Design - **Trial Structure**: Three arms including placebo and two doses (1.8 mg and 2.4 mg), with a focus on good tolerability observed in Phase 2 [22] - **Use of AIM-MASH AI Assist**: A novel tool to reduce variability in histology readings and improve objectivity in trial outcomes [26][29] Regulatory Considerations - **FDA Discussions**: Ongoing discussions with the FDA regarding the use of non-invasive tests (NITs) as endpoints, with current data being captured for potential future discussions [35] Market Potential - **AUD Population**: Estimated 12 million individuals in the AUD category, with a significant unmet need for effective treatments [50] - **Pricing Strategy**: Anticipation of different pricing strategies for MASH and AUD therapies, with a focus on differentiation and value [52][53] Additional Insights - **Enrollment Timelines**: Expectation to complete enrollment for trials within 18-24 months, leveraging strong site relationships and previous trial learnings [38] - **Patient-Reported Outcomes**: Emphasis on capturing both subjective and objective measures of treatment efficacy in AUD trials [40][41] Conclusion - Altimmune is positioned for a significant year ahead with multiple ongoing trials and a focus on innovative treatment approaches for liver diseases, particularly through the development of pemvidutide. The company is actively working on strengthening its financial position and preparing for Phase 3 trials while engaging with regulatory bodies to optimize trial outcomes and market entry strategies.

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune - **Event**: Leerink Partners Global Healthcare Conference - **Key Participants**: CEO Jerry Durso, CMO Christophe Arbet-Engels, CFO Greg Weaver Industry Focus - **Primary Focus**: MASH (Metabolic Associated Steatotic Liver Disease) - **Clinical Trials**: Phase 2 and Phase 3 trials for pemvidutide, a treatment for MASH and other liver-related diseases Key Points and Arguments Clinical Data and Regulatory Progress - **2025 Highlights**: Significant clinical data expected, including two readouts from the Phase 2 MASH trial in 2025, with 24-week and 48-week data showing promising results for pemvidutide [6][18] - **Regulatory Feedback**: Received breakthrough therapy designation from the FDA, indicating strong alignment on Phase 3 trial design [6][34] - **Phase 3 Trial**: Focus on a 52-week endpoint to assess antifibrotic effects, with a simple titration scheme for dosing to improve tolerability [20][27] Pemvidutide Differentiation - **Mechanism of Action**: Pemvidutide combines glucagon and GLP-1 in a 1:1 ratio, which is believed to provide a balanced therapeutic effect, unlike competitors like survodutide, which has a 7:1 ratio favoring GLP-1 [10][12] - **Tolerability**: Pemvidutide shows lower discontinuation rates compared to other treatments, with less than placebo rates of discontinuation [13][33] - **Efficacy**: Strong indications of antifibrotic effects observed in non-invasive tests, with confidence in achieving significant results in the upcoming Phase 3 trial [18][19] Market Position and Strategy - **Patient Segmentation**: Physicians are expected to segment patients based on tolerability and efficacy, with pemvidutide positioned as a favorable option for patients who struggle with other incretin therapies [63][64] - **Combination Therapy Potential**: Pemvidutide may serve as a complementary agent in combination therapies, enhancing efficacy without increasing side effects [58][59] Upcoming Trials and Endpoints - **Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ALD)**: Two unique Phase 2 programs are underway, targeting large unmet needs in these areas [67][68] - **Endpoints for AUD**: Focus on reducing heavy drinking days, with a target of a 1-day reduction in average heavy drinking days as a meaningful clinical outcome [75][77] Regulatory Considerations - **FDA Engagement**: Ongoing discussions with the FDA regarding the use of non-invasive tests (NITs) for regulatory approval, with potential for evolving acceptance during the trial [42][46] - **Global Alignment**: Efforts to align with European regulatory bodies (EMA, MHRA) to ensure a cohesive global strategy for pemvidutide [51] Additional Important Insights - **Long-term Market Outlook**: The MASH market is expected to evolve similarly to the diabetes market, with multiple mechanisms and treatment options becoming available [65] - **Focus on F4 Population**: While the primary focus remains on F2 and F3 populations, there is potential for future exploration in the F4 compensated cirrhotic population [54] This summary encapsulates the critical insights and strategic directions discussed during the Altimmune conference call, highlighting the company's focus on advancing pemvidutide as a leading treatment option in the MASH and liver disease landscape.